A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant...

Area of Science:

• Oncology
• Real-world Evidence
• Prostate Cancer Research

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) poses treatment challenges.
• Androgen deprivation therapy (ADT) has limited long-term efficacy for most patients.
• Real-world data is crucial for understanding mCRPC treatment patterns and unmet needs.

Purpose of the Study:

• To analyze treatment patterns for mCRPC in real-world settings outside the US and Europe.
• To identify patient attrition rates across treatment lines.
• To understand reasons for treatment discontinuation in mCRPC.

Main Methods:

• Multi-country, retrospective, non-interventional study.
• 31 centers in Latin America, the Middle East, and Asia.
• Analysis of treatment patterns in mCRPC, mCSPC, and nmCRPC settings (Jan 2016-Dec 2018).

Main Results:

• Significant patient attrition observed: ~50% to 2L, 23.5% to 3L.
• New hormonal agent (NHA)-based therapies were common in 1L and 2L.
• Disease progression was the primary reason for discontinuation (>60%), with decreasing real-world progression-free survival (rwPFS) per line.

Conclusions:

• Provides valuable real-world insights into mCRPC treatment landscape in non-US/European regions.
• Highlights significant attrition and disease progression as key challenges.
• Suggests potential unmet needs in mCRPC management in these areas.